Intrexon Buys Stem Cell Tech Developer Medistem for $26M – Genetic Engineering News
|
Intrexon Buys Stem Cell Tech Developer Medistem for $26M
Genetic Engineering News The combined company plans to develop two classes of clinical products—stem cells designed for therapeutic delivery of secreted proteins, and exosomes capable of delivering miRNAs and proteins, Thomas Reed, Ph.D., Intrexon’s CSO, said in a statement. Intrexon to Acquire Medistem to Generate Multipotent CellsWall Street Journal |
